Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

Next Previous
X
Search
Trial Profile

A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Facial wrinkles
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Revance Therapeutics

    • Most Recent Events

    • 09 Nov 2020 According to a Revance Therapeutics media release, a 4-week interim analysis from the study was presented at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting 2020.
    • 06 Oct 2020 According to a Revance Therapeutics media release, The data from the LCL study were used to optimize our Phase 2 open-label upper facial lines study
    • 06 Oct 2020 According to a Revance Therapeutics media release, the company will present one oral presentation featuring new interim analysis data from this Phase 2a open-label study at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top